The relationship between interleukin 17A rs2275913 gene polymorphism and circulating IL17A levels and disease activity and severity in Egyptian rheumatoid arthritis patients.

IL17A, part of the IL17 cytokine family, is a pivotal player in synovitis present in RA patients. This research focused on assessing how the IL17A rs2275913 genetic variation influences IL17A serum concentration, disease progression and prognosis in Egyptian RA patients. It encompassed a group of 100 healthy individuals and 100 RA patients. The rs2275913 genetic polymorphism was analyzed in both groups using the Taqman genotyping assay. Additionally, IL17A serum concentration was examined through the ELISA technique. RA patients demonstrated significantly elevated IL17A serum levels compared to control subjects (122 ± 32.5 Pg/mL vs 20.5 ± 2.8 Pg/mL, p < 0.001). Moreover, the prevalence of the rs2275913 G allele was higher in RA patients than in normal individuals (p < 0.001). Those with the GG genotype exhibited increased levels of all parameters related to disease severity and activity. Individuals with the GG genotype exhibited elevated IL17A serum levels in comparison to those with GA and AA genotypes (127.9 ± 29.9 Pg/mL vs 111.1 ± 34.6 Pg/mL, p = 0.013). In summary, the IL17A rs2275913 gene polymorphism has an impact on IL17A serum production, therefore it has role in diseases pathogenesis, and it is linked to increased disease severity in Egyptian RA patients.